Private Capital Advisors Inc. bought a new stake in shares of Celgene Co. (NASDAQ:CELG) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 15,751 shares of the biopharmaceutical company’s stock, valued at approximately $2,297,000.
A number of other large investors have also bought and sold shares of CELG. Johnson Financial Group Inc. lifted its position in shares of Celgene by 4.5% during the second quarter. Johnson Financial Group Inc. now owns 13,100 shares of the biopharmaceutical company’s stock worth $1,040,000 after purchasing an additional 567 shares in the last quarter. Wetherby Asset Management Inc. lifted its position in shares of Celgene by 5.4% during the second quarter. Wetherby Asset Management Inc. now owns 11,857 shares of the biopharmaceutical company’s stock worth $942,000 after purchasing an additional 603 shares in the last quarter. Tompkins Financial Corp lifted its position in shares of Celgene by 3.8% during the second quarter. Tompkins Financial Corp now owns 18,059 shares of the biopharmaceutical company’s stock worth $1,434,000 after purchasing an additional 656 shares in the last quarter. Coastline Trust Co lifted its position in shares of Celgene by 14.5% during the second quarter. Coastline Trust Co now owns 5,370 shares of the biopharmaceutical company’s stock worth $427,000 after purchasing an additional 680 shares in the last quarter. Finally, BancorpSouth Bank lifted its position in shares of Celgene by 11.8% during the second quarter. BancorpSouth Bank now owns 6,591 shares of the biopharmaceutical company’s stock worth $523,000 after purchasing an additional 697 shares in the last quarter. Hedge funds and other institutional investors own 73.11% of the company’s stock.
A number of research firms have recently commented on CELG. Standpoint Research raised shares of Celgene from a “hold” rating to a “buy” rating in a research report on Monday, June 18th. BidaskClub cut shares of Celgene from a “buy” rating to a “hold” rating in a research report on Thursday, September 13th. Cantor Fitzgerald assumed coverage on shares of Celgene in a report on Monday, October 1st. They issued an “overweight” rating and a $100.00 price target on the stock. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Celgene in a report on Thursday. Finally, Morgan Stanley upped their price target on shares of Celgene from $90.00 to $91.00 and gave the company an “equal weight” rating in a report on Friday, July 13th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company’s stock. Celgene presently has an average rating of “Buy” and an average price target of $121.42.
CELG stock traded up $1.87 during trading on Friday, hitting $82.58. 4,766,800 shares of the company’s stock traded hands, compared to its average volume of 6,501,751. The company has a debt-to-equity ratio of 5.76, a current ratio of 1.52 and a quick ratio of 1.40. Celgene Co. has a 52 week low of $74.13 and a 52 week high of $139.72. The firm has a market cap of $62.94 billion, a price-to-earnings ratio of 11.90, a PEG ratio of 0.54 and a beta of 1.30.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.16 earnings per share for the quarter, beating the consensus estimate of $2.11 by $0.05. Celgene had a net margin of 19.81% and a return on equity of 87.28%. The firm had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.70 billion. During the same quarter in the previous year, the firm earned $1.82 earnings per share. The firm’s revenue for the quarter was up 16.6% compared to the same quarter last year. As a group, analysts expect that Celgene Co. will post 7.64 EPS for the current fiscal year.
In other Celgene news, Director Ernest Mario sold 12,000 shares of the business’s stock in a transaction on Thursday, August 9th. The shares were sold at an average price of $92.32, for a total transaction of $1,107,840.00. Following the completion of the sale, the director now owns 44,413 shares in the company, valued at $4,100,208.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director John H. Weiland bought 5,575 shares of the stock in a transaction on Tuesday, August 7th. The shares were acquired at an average price of $89.73 per share, with a total value of $500,244.75. The disclosure for this purchase can be found here. 0.39% of the stock is owned by insiders.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: Why do earnings reports matter?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.